Successful Treatment of Cutaneous Larva Migrans With Combined Albendazole and Ivermectin Therapy: A Report of Two Cases From Sudan

TL;DR

Two cases of skin infection from hookworm larvae were successfully treated with a combination of two drugs, showing promise for managing this condition.

Contribution

Demonstrates successful use of combined albendazole and ivermectin therapy for cutaneous larva migrans.

Findings

Two Sudanese patients with cutaneous larva migrans were fully treated with albendazole and ivermectin.

Lesions resolved completely within one week without recurrence.

Combination therapy may be effective amid antihelminthic resistance.

Abstract

Cutaneous larva migrans (CLM), caused by third-stage filariform larvae of cat and dog hookworms, presents as pruritic, serpiginous tracks upon skin penetration by larvae from contaminated soil. Herein, we report the successful treatment of two CLM patients using albendazole and ivermectin combination therapy. A 42-year-old man from Kordofan and a 38-year-old man from White Nile State presented with characteristic lesions on their lower extremities, resolving completely within one week post-treatment without recurrence. This report highlights the potential of combined albendazole-ivermectin therapy in managing CLM amid emerging antihelminthic resistance, suggesting that its broader application warrants further investigation.

Figures